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Abstract
Introduction: On-treatment HCV RNA measurements are crucial for the prediction of a sustained virological response (SVR)
and to determine treatment futility during protease inhibitor-based triple therapies. In patients with advanced liver disease
an accurate risk/benefit calculation based on reliable HCV RNA results can reduce the number of adverse events. However,
the different available HCV RNA assays vary in their diagnostic performance.
Aim: To investigate the clinical relevance of concordant and discordant results of two HCV RNA assays during triple therapy
with boceprevir and telaprevir in patients with advanced liver fibrosis/cirrhosis.
Methods: We collected on-treatment samples of 191 patients with advanced liver fibrosis/cirrhosis treated at four European
centers for testing with the Abbott RealTime (ART) and COBAS AmpliPrep/COBAS TaqMan HCV v2.0 (CTM) assays.
Results: Discordant test results for HCV RNA detectability were observed in 23% at week 4, 17% at week 8/12 and 9% at
week 24 on-treatment. The ART detected HCV RNA in 41% of week 4 samples tested negative by the CTM. However, the
positive predictive value of an undetectable week 4 result for SVR was similar for both assays (80% and 82%). Discordance
was also found for application of stopping rules. In 27% of patients who met stopping rules by CTM the ART measured
levels below the respective cut-offs of 100 and 1000 IU/ml, respectively, which would have resulted in treatment
continuation. In contrast, in nine patients with negative HCV RNA by CTM at week 24 treatment would have been
discontinued due to detectable residual HCV RNA by the ART assay. Importantly, only 4 of these patients failed to achieve
SVR.
Conclusion: Application of stopping rules determined in approval studies by one assay to other HCV RNA assays in clinical
practice may lead to over and undertreatment in a significant number of patients undergoing protease inhibitor-based
triple therapy.
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Introduction
Chronic hepatitis C is a major cause for liver transplantation
and hepatocellular carcinoma worldwide [1,2]. A successful viral
eradication leads to a significant improvement of the overall
survival rate and reduces liver related morbidity [3]. Efficacy of
antiviral therapy markedly increased with the development of
direct acting antiviral agents (DAAs). In 2011, the first generation
of DAAs, the protease inhibitors (PIs) telaprevir (TVR) and
boceprevir (BOC), were approved for treatment of chronic
hepatitis C virus (HCV) genotype (GT) 1 infection [4–8]. More
recently, a third PI, simeprevir (SMV) has been approved in the
US, Canada and Japan [9]. Furthermore, the polymerase-
inhibitor sofosbuvir (SOF) was most recently marketed in the US
and some European countries. More DAAs will soon be approved.
Second generation DAAs will certainly lead to an improved safety
and efficacy of HCV treatment [9–11]. However, so far standard
treatment in most GT1 patients is still based on pegylated-
interferon and ribavirin (P/R). Furthermore, due to high costs, it
will likely take quite some time until SOF and SMV will be
approved and available in most parts of the world, as several
countries have only recently attained access to BOC and TVR or
are even still awaiting the approval or reimbursement of first
generation PIs.
In several real-life cohorts of patients with advanced liver
disease the frequency of serious adverse events was high when
treated with first generation PI-based triple therapy. In particular
severe infections and hepatic decompensations were a significant
problem. Even lethal complications have been documented.
Furthermore, efficacy was also lower compared with those in
patients with no or only mild fibrosis [12–14]. Thus, in order to
ensure a reasonable risk/benefit ratio in patients with urgent need
of antiviral therapy, but increased risks of serious adverse events, it
is crucial to establish predictive factors for a sustained virological
response. While there are a number of baseline predictors, the
most important response parameter during treatment remains
HCV RNA viral kinetics [15]. Here in particular, the difference
between undetectable HCV RNA and residual HCV viremia may
be of high prognostic value [16,17]. In addition, quantitative HCV
RNA levels at certain time points during PI-based triple therapy
determine treatment futility [2]. By early discontinuation of
unlikely to succeed therapies, accurate futility rules may prevent
not only unnecessary side-effects but also reduce therapy-related
costs.
A number of different HCV RNA assays with variable
sensitivities and accuracies are used in clinical practice. However,
only little is known regarding the extent to which different assay
performances may influence the management of PI-based triple
therapies including determination of treatment duration and early
discontinuation of antiviral therapy. Furthermore, it is not clear
whether individual assay performances may lead to differences in
the predictive value and/or the sensitivity to identify patients who
are at risk of treatment failure and for whom the risk of treatment
associated toxicity might be unacceptable.
We here compared the performance of two HCV RNA assays,
the Abbott RealTime HCV Test (ART) and the COBAS
AmpliPrep/COBAS TaqMan HCV Test v2.0 (CTM) [18,19],
in patients with advanced liver fibrosis/cirrhosis who were treated
with TVR- and BOC-based triple therapy in four European
centers. We analyzed the impact of the two assays on stopping
rules and the predictive value for achieving SVR.
Patients and Methods
Patients
A total number of 191 HCV genotype 1 monoinfected patients
was included from four European study sites: Hannover Medical
School (Hanover, Germany), University of Palermo (Palermo,
Italy), Saint La´szlo´ Hospital (Budapest, Hungary) and Somogy
County Kaposi Mo´r Teaching Hospital (Kaposva´r, Hungary).
Patients with HBV or HIV infection were excluded. HCV
subgenotype was available for 169 (88%) patients, of whom 87%
were infected with HCV GT 1b. All patients had advanced liver
fibrosis or cirrhosis (METAVIR F3/F4) as determined by liver
biopsy, transient elastography or obvious clinical signs. Patients
were treated with TVR (n= 65) or BOC (n= 126) in combination
with P/R according to the respective prescribing information and
international guidelines [20,21].
HCV RNA measurements
Patient samples were collected at 4, 8 (BOC), 12 (TVR) and/or
24 weeks after the start of PI treatment, the key decision time
points for response-guided treatment and/or stopping criteria
[2,20,21]. All samples were first tested with the COBAS
AmpliPrep/COBAS TaqMan HCV Test v2.0 (CTM) (limit of
quantification = LOQ: 15 IU/ml; limit of detection = LOD:
15 IU/ml) and retrospectively re-tested with the Abbott RealTime
HCV Test (ART) (LOQ and LOD: 12 IU/ml) according to the
manufactures’ instructions. Treatment decisions were based on the
CTM results. At each time point, only those patients in whom the
respective sample volume was sufficient for re-testing with the
ART were included in the later analysis.
Selection of samples for the analysis of the concordance
in patients with no or only residual viremia
For the analysis of concordance in differentiating samples with
low residual viremia from those that were HCV RNA negative,
only samples with an HCV RNA,50 IU/ml in at least one of the
two tests were considered.
Selection of samples for determining the assays’
concordance at HCV RNA levels close to the threshold of
stopping rules
One objective of this study was to determine the concordance
between the two assays at HCV RNA levels leading to
discontinuation of therapy due to the recommended stopping
criteria. For this purpose only those samples were considered that
had an HCV RNA level of $50 IU/ml in at least one of the two
assays. At week 24 all samples with detectable HCV RNA in at
least one of the two tests were considered.
Statistics
Data were collected with Microsoft Excel (Microsoft, Redmond,
Washington, USA) and analyzed with GraphPad Prism for Mac
(version 6.0; GraphPad Software Inc., La Jolla, California, USA).
Ethics
This study was performed according to the Declaration of
Helsinki. The local ethical committee of Hannover Medical
School approved the retrospective, anonymous retesting of patient
samples, and the anonymous analyzing of patient data without the
need for a written informed consent.
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Results
Assay concordance in low viremic or HCV RNA negative
samples obtained during triple therapy
Concordance between the two assays in classifying samples as
HCV RNA positive or negative varied among the different time
points. Overall, we observed an increasing concordance during
later stages of therapy starting at 77% at week 4, 83% at week 8/
12 and 91% at week 24 (Table 1).
However, in week 4 samples the relative sensitivity to detect
residual HCV RNA by the CTM assay was low. Retesting of these
week 4 samples with the ART assay revealed detectable HCV
RNA in 41%. In contrast, the CTM detected HCV RNA in 19%
of the samples with an undetectable result in the ART assay
(Table 1).
Similar results were observed at week 8/12 of therapy.
Retesting with the ART detected HCV RNA in 14 samples that
were not identified as HCV RNA positive in the initial
measurement with the CTM. In contrast, the CTM also produced
8 positive results in samples classified as negative if retested with
the ART (Table 1). However, due to a higher total number of
negative tested samples reliability of an undetectable result was far
higher compared with week 4 (ART: 93% vs. 81%; CTM: 85% vs.
59%). The observed differences between the two HCV RNA
assays overall were not influenced by the used PI (TVR or BOC).
Still, due to the shorter PI treatment duration, there were more
positive samples in patients treated with BOC. Subsequently,
reliability of an undetectable result was lower after 8 weeks of
BOC treatment compared to samples obtained after 12 weeks of
TVR treatment (Table 1).
Table 1. Concordance and discordance between the ART and the CTM in classifying samples as HCV RNA undetectable or low
viremic (,50 IU/ml) obtained 4, 8 (BOC), 12 (TVR) and 24 weeks after the start of PI-based treatment.
CTM
Not detectable Detectable Discordance Overall Concordance/Discordance
4 weeks after
PI therapy
ART Not Detectable 17 4 19% (4/21) 77% (54/70)/23% (16/70)
Detectable 12 37
Discordance 41% (12/29)
4 weeks after
TVR therapy
ART Not Detectable 15 4 21% (4/19) 73% (41/56)/27% (15/56)
Detectable 11 26
Discordance 42% (11/26)
4 weeks after
BOC therapy
ART Not Detectable 2 0 0% (0/2) 93% (13/14)/7% (1/14)
Detectable 1 11
Discordance 33% (1/3)
8/12 weeks
after PI therapy
ART Not Detectable 78 8 9% (8/86) 83% (104/126)/17% (22/126)
Detectable 14 26
Discordance 15% (14/92)
12 weeks after
TVR therapy
ART Not Detectable 45 2 4% (2/47) 87% (46/53)/13% (7/53)
Detectable 5 1
Discordance 10% (5/50)
8 weeks after
BOC therapy
ART Not Detectable 33 6 15% (6/39) 80% (58/73)/20% (15/73)
Detectable 9 25
Discordance 21% (9/42)
24 weeks after
PI therapy
ART Not Detectable 93 1 1% (1/94) 91% (99/109)/9% (10/109)
Detectable 9 6
Discordance 9% (9/102)
24 weeks after
TVR therapy
ART Not Detectable 38 0 0% (0/38) 93% (39/42)/7% (3/42)
Detectable 3 1
Discordance 7% (3/41)
24 weeks after
BOC therapy
ART Not Detectable 55 1 2% (1/56) 90% (60/67)/10% (7/67)
Detectable 6 5
Discordance 10% (6/61)
doi:10.1371/journal.pone.0110857.t001
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At week 24, the vast majority of samples tested negative for
HCV RNA by both assays (85%). Again a few samples (n = 9)
tested negative by the CTM revealed detectable HCV RNA after
retesting with the ART. In contrast, only a single sample that was
not detected with the ART produced a positive result in the initial
measurement with the CTM. Results for week 24 were also similar
for both PIs (Table 1).
Predictive value of concordant/discordant low viremic
(,50 IU/ml) or negative HCV RNA results for the final
treatment outcome
On-treatment HCV RNA results had a high prognostic value
for the final treatment outcome. Patients with an undetectable
HCV RNA result by CTM four weeks after PI therapy achieved a
SVR in 82% (n= 23/28) compared to only 54% (n= 22/41) of
those with detectable low viremia (HCV RNA ,50 IU/ml).
Similar results were documented for the ART with an 80%
(n= 16/20) and a 59% (n= 29/49) SVR rate in those with an
undetectable and a detectable low viremic week 4 HCV RNA
result, respectively. Interestingly, SVR rate increased from 69%
(n=11/16) in patients with only one undetectable HCV RNA
result up to 88% (n= 14/16) in those who were undetectable with
both assays at week 4 (Figure 1a). Sensitivity to detect a patient
with a later treatment failure by a low viremic week 4 sample was
83% for the ART, 79% for the CTM and 92% using both assays.
Similar results were observed at week 8/12. Patients with
undetectable HCV RNA by CTM and ART at this stage were
cured in 69% (n= 62/90) and 67% (n= 56/83), respectively. In
contrast, among those with a detectable low viremic result by
CTM, only 30% (n= 9/30) achieved SVR whereas still 41%
(n= 15/37) were detectable with the ART. Nevertheless SVR
chances were still markedly lower in those patients, in whom only
one of the two assays produced a negative HCV RNA result
compared to those, in whom testing with the CTM as well as
retesting with the ART did not detect any HCV RNA (48% vs.
71%) (Figure 1b). Interestingly, not a single patient with quanti-
fiable HCV RNA at week 8/12 (n= 8) in at least one of the two
assays achieved SVR. Overall, data were similar for both PIs.
However, all three patients that had still a detectable low viremic
HCV RNA level after 12 weeks of TVR treatment by the CTM
experienced a treatment failure, while SVR rate was 50% amongst
the six patients that yielded a detectable level by ART. Sensitivity
to identify a patient with a later treatment failure by residual
viremia was 45% using the ART, 43% with the CTM and
increased to 55% using both assays.
Assay concordance in samples with quantifiable HCV
RNA and in determining treatment futility
There were 56 samples available with quantifiable HCV RNA
$50 IU/ml (range: 1.08–6.50 log IU/ml). Again, all samples were
first tested with the CTM and afterwards retested with the ART.
Correlation between the CTM and the ART was good in these
samples (Spearman correlation: r = 0.9) (Figure 2). However, the
CTM tended to yield higher levels compared with the ART.
Overall, HCV RNA levels were higher with the CTM test in 91%
of the samples. The mean log difference between the measured
HCV RNA levels in both assays was 0.53 log IU/ml (range: 0.04–
1.84 log IU/ml).
There were eight patients with an HCV RNA level $50 IU/ml
after 4 weeks of TVR treatment (13% of all TVR treated patients).
Two patients had a level $1000 IU/ml in the CTM assay, where
stopping of all antiviral treatment is recommended. Interestingly,
none of these patients had an HCV RNA level.1000 IU/ml in
the ART and would therefore had been kept on treatment
according to the ART assay. One of these patients continued
treatment but experienced a virological breakthrough by week 12
of therapy. Similar results were observed in patients after four
weeks of BOC treatment. Overall four patients had an HCV RNA
result $50 IU/ml including two with a level.1000 IU/ml. All
four samples had HCV RNA levels ,50 IU/ml if re-tested with
the ART (Table 2).
At week 12 of TVR treatment only two out of three patients
with an HCV RNA level above the threshold for treatment futility
in the CTM test would have been withdrawn from treatment using
the results from retesting with the ART (Table 3). Assay
concordance was higher at week 8 after start of BOC treatment.
Overall, 80% of the patients with an HCV RNA level.100 IU/
ml in the CTM (n= 25) had HCV RNA levels above this limit also
in the ART. However, this was mainly due to the fact that 40%
had levels.1log above the recommended threshold for stopping of
all medication (Table 4).
In contrast to weeks 4 and 12 of treatment, using the ART
would have lead to more treatment discontinuations at week 24
than the CTM. With the CTM, 21 patients matched the
recommended stopping criteria, which is any detectable HCV
RNA at this stage. Retesting with the ART confirmed detectable
HCV RNA in all of these samples except for a single one. In
contrast, re-testing with the ART revealed detectable HCV RNA
but below the LOQ (,12 IU/ml) in nine samples that were
previously tested negative by CTM, as described earlier (Table 5).
According to the ART, all nine patients should have stopped
antiviral treatment based on current recommendations. Interest-
ingly, SVR was achieved in four out of the eight patients (50%), for
whom follow-up data were available. The majority of patients with
detectable HCV RNA by CTM at week 24 were considered
treatment failures according to the recommended stopping rules
and withdrawn from treatment. In six patients, treatment was
continued despite a detectable low viremic HCV RNA in the
CTM. One patient was lost to follow up. The remaining five
patients all experienced a relapse or breakthrough. Overall,
sensitivity to identify a patient with a later treatment failure by
residual viremia at week 24 was 33% using the ART and 20%
with the CTM.
Discussion
On-treatment HCV RNA measurements are crucial for the
prediction of a sustained virological response (SVR) and determi-
nation of treatment futility during the majority of modern HCV
therapies. However, there are several commercially available
HCV RNA assays, which differ in absolute HCV RNA
quantification and lower detection limits [22,23]. We here showed
that there are significant differences in the performance of two
HCV RNA tests, the Abbott RealTime test (ART) and the
COBAS AmpliPrep/COBAS TaqMan HCV Test v2.0 (CTM) in
classifying samples obtained from patients with advanced liver
fibrosis or cirrhosis undergoing antiviral treatment with first
generation HCV protease inhibitors (PIs). While both assays are
comparable in their positive predictive value for SVR, there are
remarkable differences in determining treatment futility. A
significant number of successful viral clearances are missed if
treatment is unnecessarily stopped due to detectable HCV RNA
with the ART assay at week 24 of triple therapy, as it is currently
recommended in the prescribing information and in international
guidelines [21], while an almost equal number of patients were
overtreated due to undetectable virus by CTM at this time point.
In contrast, at earlier time points of PI-based triple therapy more
Performance of Two HCV RNA Assays during PI-Based Triple Therapy
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patients may continue treatment due to lower absolute quantita-
tive HCV RNA levels in the ART.
There are three aspects that are of particular importance for on-
treatment HCV RNA measurement during most modern PI-based
triple therapies: i) it is used to predict the likelihood for a later
SVR, ii) to select patients for an abbreviated treatment regimen
(response-guided therapy), and iii) to determine treatment futility.
In the TVR and BOC registration trials, the chance of SVR was
higher in patients with an undetectable HCV RNA result
compared to those with detectable HCV RNA even at levels
below the assays limit of quantification (LOQ) at several different
time points of antiviral treatment [16]. However, in most DAA
drug trials including the registration studies for BOC, TVR, as
well as the second generation DAAs like simeprevir (SMV) and
sofosbuvir (SOF), treatment response was measured with the
Cobas TaqMan assay for use with the manual HighPure
extraction kit (HPS). Contrarily, the HPS test is rarely used in
routine clinical practice and seems to be slightly less sensitive in
detecting low HCV RNA levels compared with the ART or the
CTM [17,24,25]. We here confirmed in patients with advanced
liver disease that an undetectable HCV RNA result early during
therapy is a strong predictor for achieving SVR also if the CTM or
Figure 1. Predictive value of HCV RNA results in the CTM and ART at week 4 (a) and week 8/12 (b) after start of therapy with a
protease inhibitor. TND = target not detected; DET = HCV RNA detected; TND/TND = HCV not detected in both assays; TND/DET = HCV RNA
detected by only one assay; DET/DET: HCV RNA detected by both assays. *Patients with unavailable virological treatment outcome were excluded
from analysis.
doi:10.1371/journal.pone.0110857.g001
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the ART are used for HCV quantification. Of note, the ART was
able to detect HCV RNA in several samples which produced an
HCV RNA negative result in the CTM, while this was rarely
observed the other way around. Similar results have been
documented in a recently published study investigating the impact
of the ART and CTM on response guided TVR-based triple
therapy. Fewer patients would have been eligible for the shorter
treatment duration if the ART would have been used to assess
HCV RNA undetectability at week 4 due to a higher test
sensitivity of this assay [26]. In our study, we focused on difficult-
to-treat patients with advanced liver disease of whom in principle
only a minority qualifies for shorter treatment duration. In these
kinds of patients, it is crucial to ensure high SVR chances in order
to justify the significant safety concerns that are associated with PI-
based triple therapy. It was recently shown that patients with a
repeatedly confirmed undetectable HCV RNA result during PI-
based treatment have significantly higher chances to attain SVR
compared with patients in whom repeated testing reveals
detectable HCV RNA despite an initially undetectable HCV
RNA result [17]. This was again observed in the present study.
Patients with an undetectable HCV RNA result according to both
ART and CTM had the highest chance for achieving SVR.
However, despite the higher sensitivity of the ART and
subsequently the larger number of samples identified as HCV
RNA positive, the positive predictive value was not superior
compared to the CTM. Overall, there was no clear advantage of
using either of the assays in SVR prediction based on early HCV
RNA measurements.
The second objective of our study addressed for the first time
the impact of different performances of the ART and the CTM on
stopping rules. Overall, there were two major findings. First, in
samples with quantifiable HCV RNA, the ART tends to measure
lower absolute HCV RNA levels. Consequently, more patients are
likely to pass the HCV RNA cut-off of 1000 IU/ml at weeks 4 and
12 for TVR or 100 IU/ml at week 12 for BOC that are required
to continue treatment. As the CTM was used to determine
treatment futility in our patients, we were not able to study
whether using the ART either leads to overtreatment of patients
with poor chances for SVR or whether it prevents unnecessary
early treatment discontinuations. However, in one patient who
continued treatment despite formal futility at week 4 by CTM, but
not by the ART assay, a breakthrough later during therapy was
observed. Of course, no definite conclusion can be drawn form this
observation in a single patient. To determine treatment futility it
has to be considered that absolute cut-off levels for stopping rules
have never been investigated in prospective trials. However, all
patients with any quantifiable HCV RNA after more than four
weeks of PI therapy had relatively low chances to achieve SVR
during the pivotal trials [27]. In our study, all patients with
quantifiable HCV RNA at week 8 or 12 experienced a treatment
failure. This was the case even for those patients with levels below
Figure 2. Correlation between the CTM and the ART in samples
with quantifiable HCV RNA levels. r: Spearman correlation; p: p-
value.
doi:10.1371/journal.pone.0110857.g002
Table 2. HCV RNA levels according to ART and CTM in samples obtained 4 weeks after start of TVR/BOC therapy that yielded levels
$50 IU/ml in at least one of the two assays.
CTM ART
TVR 1 2440 431
2 2150 295
3 665 237
4 320 104
5 190 35
6 91 ,12
7 85 ,12
8 59 91
BOC 1 2620 38
2 1570 36
3 77 34
4 70 ,12
The discordant results in two samples (‘‘TVR 1’’ and ‘‘TVR 2’’) would have led to different treatment decisions (treatment discontinuation based on HCV RNA levels.
1000 IU/ml at week 4). In a single sample the ART measured a higher HCV RNA level than the CTM (‘‘TVR 8’’).
doi:10.1371/journal.pone.0110857.t002
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the recommended cut-offs in both assays. The second important
finding was that, contrarily, at week 24 after start of PI therapy,
residual HCV RNA was detected with the ART in several patients
in whom the CTM produced HCV RNA negative results. All of
these samples yielded levels below the LOQ of the ART (,12 IU/
ml). Still, when referring to the current guidelines these patients
would have been withdrawn from treatment according to the ART
result [2,20,21]. However, half of these patients did ultimately
achieve SVR. It has been suggested in other studies that at least at
early time points of PI containing triple therapy a detectable HCV
RNA result ,12 IU/ml in the ART might be equal to an
undetectable result with the CTM [26]. Based on our data, we
Table 3. HCV RNA levels according to ART and CTM in samples obtained 12 weeks after TVR treatment that yielded levels $50 IU/
ml in at least one of the two assays.
CTM ART
TVR 1 17200 2502
2 6990 2046
3 4220 832
4 959 186
The discordant results in one sample (‘‘TVR 3’’) would have led to a different treatment decision (treatment discontinuation based on HCV RNA levels.1000 IU/ml at
week 4).
doi:10.1371/journal.pone.0110857.t003
Table 4. HCV RNA levels according to ART and CTM measured in samples obtained 8 weeks after BOC treatment that yielded
levels of $50 IU/ml in at least one of the two assays.
CTM ART
BOC 1 664000 371593
2 176000 607115
3 116000 44381
4 28200 17099
5 24300 32598
6 7230 2556
7 4660 2485
8 1580 1027
9 1120 430
10 1080 229
11 891 482
12 840 356
13 735 281
14 510 217
15 408 226
16 397 132
17 367 134
18 344 177
19 280 226
20 151 105
21 650 79
22 529 67
23 344 ,12
24 231 62
25 176 59
26 64 24
27 52 31
28 47 80
The discordant results in five samples (‘‘BOC 21–25’’) would have led to different treatment decisions (treatment discontinuation based on HCV RNA levels.100 IU/ml).
In a single sample the ART measured a higher HCV RNA level than the CTM (‘‘BOC 28’’).
doi:10.1371/journal.pone.0110857.t004
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believe that a detectable HCV RNA below the LOQ in the ART
(,12 IU/ml detectable) at week 24 of TVR- or BOC-based triple
therapy should not be considered as a necessary stopping rule.
Instead, treatment continuation should be discussed in these
patients based on their individual treatment associated risks.
Whether residual viremia by the ART assay at later time points
during treatment may be predictive for virological relapse has to
be explored in future studies. It must be noted, however, that in a
recent IFN-free DAA study residual HCV RNA could be detected
by ART as late as end-of-treatment in some patients who
subsequently achieved SVR [28].
Limitations of our study include the retrospective design and the
relatively small patient number in certain subgroups. In addition,
it has to be stated that all samples were first tested with the CTM
and then retested with the ART. All patients were managed
according to the respective HCV RNA result in the CTM. Thus, a
direct comparison to patients that were treated according to the
HCV RNA results by the ART was not possible. Due to limited
sample volumes we were only able to test each sample once with
the ART and the CTM. Thus, we were not able to study the
impact of intra-assay variability. However, this question has been
addressed in several other studies. In samples with quantifiable
HCV RNA intra-assay variability were demonstrated to be low for
both assays [29–31]. Per definition, a detectability rate of.95% is
required at HCV RNA levels$LOD. In samples with levels below
the LOD, intra-assay variability is significantly higher for both
assays and varies depending on the respective HCV RNA level
[17,24,29–31]. As BOC and TVR are only approved for HCV
GT1, other HCV genotypes could not be studied here. We were
also not able to analyze the impact of the HCV subgentoype (1a or
1b) as this information was not available for all patients an only a
minority of the included patients was infected with HCV GT 1a.
Our data may be less relevant for some newer antiviral regimens
including those containing the NS5B polymerase-inhibitor sofos-
buvir (SOF) that have recently been approved in the US and some
European countries, and which do not require on-treatment HCV
Table 5. Measured HCV RNA level by the ART and CTM in samples obtained 24 weeks after TVR/BOC therapy with a detectable
HCV RNA in at least one of the two assays.
CTM ART
TVR 1 7290 2485
2 3900 1073
3 20 ,12
4 not detected ,12
5 not detected ,12
6 not detected ,12
BOC 1 3.150.000 1.341.040
2 1.660.000 520.312
3 73.700 36.725
4 49.500 25.324
5 45.100 49.652
6 13.500 2.451
7 12.800 8.845
8 4.330 1.331
9 2.100 599
10 1.210 330
11 687 87
12 238 94
13 ,15 ,12
14 ,15 ,12
15 ,15 ,12
16 ,15 ,12
17 ,15 ,12
18 ,15 not detected
19 not detected ,12
20 not detected ,12
21 not detected ,12
22 not detected ,12
23 not detected ,12
24 not detected ,12
The discordant results in ten samples (‘‘TVR 4–6’’ and ‘‘BOC 18–24’’) would have led to different treatment decisions (treatment discontinuation due to detectable HCV
RNA). In a single sample the ART measured a higher HCV RNA level than the CTM (‘‘BOC 5’’).
doi:10.1371/journal.pone.0110857.t005
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RNA measurements [32,33]. In countries with access to SOF GT1
patients can be treated with Peg-IFN/RBV/NUC triple therapy
for a fixed treatment duration of 12 weeks. Due to the fact that the
risk for viral resistance and a subsequent virological breakthrough
is extremely low, there is no need for on-treatment HCV RNA
measurements according to the prescribing information [32]. The
same affects current and upcoming IFN free all oral DAA
combination regimens. IFN free regimens consisting of SOF and
the second generation PI Simeprevir (SMV) or a NS5A-inhibitor
like daclatasvir (DCV) or ledipasvir (LDV) for a fixed, predeter-
mined duration of 8 to 24 weeks have been shown to be highly
effective also without the usage of RBV and even in patients with
liver cirrhosis and a previous null response to Peg-IFN/RBV [34–
38]. SMV is already available in several countries and the
approval of DCV is expected soon. IFN free DAA combinations
without SOF, i.e. including a NS5A-Inhibitor (ombitasvir), a non-
nucleoside NS5B-Inhibitor (dasabuvir) and a PI (ABT-450 boosted
with ritonavir) with or without RBV for 12 or 24 weeks also
achieved high SVR rates of.90% [39–42]. Due to the very high
efficacy and the excellent tolerability of these regimens, response-
guided shortening or prolongation of therapy have not been
studied and may not be needed to achieve high cure chances in the
individual patient. However, given the high costs of direct antiviral
drugs, HCV RNA testing during treatment may be helpful for
surveillance of compliance and motivation of patients. Moreover,
second generation DAAs including SOF are currently only
available in very few countries due to the high costs and regulatory
constraints. The vast majority of HCV patients currently have no
access to these newer drugs and some are still awaiting the
approval of TVR and BOC.
In summary we showed that both the Abbott RealTime Test
and the COBAS AmpliPrep/COBAS TaqMan HCV Test v2.0
can be used to measure HCV RNA during antiviral treatment
including telaprevir or boceprevir in order to predict the likelihood
of a sustained virological response. However, differences in assay
performances have to be considered. In particular the optimal
HCV RNA cut-offs for the determination of treatment futility may
differ depending on the used HCV RNA assay.
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